Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CACan-Fite BioPharma Ltd. logo

Can-Fite BioPharma Ltd. (CANF)

New York Stock Exchange Arca · Currency in USD
$1.81 ▼ -0.02 (-1.09%)
At close: Oct 23, 3:59 PM ET. Market closed.
$1.78 ▼ -0.04 (-1.93%)
After hours: Oct 23, 4:10 PM ET

Summary

Previous Close
$1.83
Open
$1.82
Day's Range
$1.77 – $1.82
52 Week Range
$1.75 – $12.40
Volume
22,969
Avg. Volume
1,235,637
Market Cap
$2.37M
Beta (5Y Monthly)
0.02
PE Ratio (TTM)
--
EPS (TTM)
-$5.15
Earnings Date
Apr 1, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$8.00

Profile: Can-Fite BioPharma Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
5
CEO
Motti Farbstein

Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19.

Earnings

Next report: Thu, Apr 1, 2027
EPS estimate -$0.80 · Revenue est. $202.00K
DateEst.Actual
Sep 8, 2026-$0.33-$1.24Miss
Mar 26, 2026-$27.00-$5.97Beat
Aug 28, 2025-$4.15-$0.00Beat
Apr 14, 2025-$0.10-$0.10Beat
Mar 27, 2025-$0.24-$0.00Beat
Jan 2, 2025-$0.27-$0.27Beat

Analyst view

Consensus price target
$8.00 ▲ +342.0%
Range $8.00 – $8.00
Rating: Buy
Buy 75% · Hold 25% · Sell 0%

Get free alerts on CANF and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.